149 related articles for article (PubMed ID: 9380990)
1. [Lymphoma].
Mohar A; Sobrevilla-Calvo P; Velasquez WS
Rev Invest Clin; 1997 May; 49 Suppl 1():56-63. PubMed ID: 9380990
[No Abstract] [Full Text] [Related]
2. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P; Passon J; Ebeling P; Welt A; Müller S; Metz K; Moritz T; Seeber S; Nowrousian MR
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[TBL] [Abstract][Full Text] [Related]
3. Conventional second-line salvage chemotherapy regimens are not warranted in patients with malignant lymphomas who have progressive disease after first-line salvage therapy regimens.
Ardeshna KM; Kakouros N; Qian W; Powell MG; Saini N; D'Sa S; Mackinnon S; Hoskin PJ; Goldstone AH; Linch DC
Br J Haematol; 2005 Aug; 130(3):363-72. PubMed ID: 16042685
[TBL] [Abstract][Full Text] [Related]
4. Hodgkin's disease.
Longo DL; Banks PM; Hoppe RT
Rev Invest Clin; 1994 Apr; Suppl():73-83. PubMed ID: 7886314
[No Abstract] [Full Text] [Related]
5. Ifosfamide, epirubicin and etoposide regimen as salvage and mobilizing therapy for relapsed/refractory lymphoma patients.
Zinzani PL; Tani M; Molinari AL; Stefoni V; Zuffa E; Alinari L; Gabriele A; Bonifazi F; Salvucci M; Tura S; Baccarani M
Haematologica; 2002 Aug; 87(8):816-21. PubMed ID: 12161357
[TBL] [Abstract][Full Text] [Related]
6. Stem cell transplantation for mantle cell lymphoma: should it ever be used outside clinical trials?
Sweetenham JW
Bone Marrow Transplant; 2001 Nov; 28(9):813-20. PubMed ID: 11781640
[TBL] [Abstract][Full Text] [Related]
7. Treatment of relapses in aggressive non Hodgkin's lymphoma.
Bosly A
Bull Cancer; 2004; 91(7-8):E261-73. PubMed ID: 15381464
[TBL] [Abstract][Full Text] [Related]
8. Comparison of ICE (ifosfamide-carboplatin-etoposide) versus DHAP (cytosine arabinoside-cisplatin-dexamethasone) as salvage chemotherapy in patients with relapsed or refractory lymphoma.
Abali H; Urün Y; Oksüzoğlu B; Budakoğlu B; Yildirim N; Güler T; Ozet G; Zengin N
Cancer Invest; 2008 May; 26(4):401-6. PubMed ID: 18443961
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease: lessons to be learned from malignant lymphoma.
Armitage JO
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():73-5. PubMed ID: 2202473
[No Abstract] [Full Text] [Related]
10. [Autologous transplant with BEAM protocol in lymphoma].
Caballero D; Rubio V; Rifon J; Heras I; García-Sanz R; Vidriales B; Pérez-Simón JA; del Cañizo C; González M; León A; Jean-Paul E; Rocha E; Vicente V; San Miguel JF
Sangre (Barc); 1997 Apr; 42 Suppl 1():46-9. PubMed ID: 9381303
[No Abstract] [Full Text] [Related]
11. [Controversies in therapy of malignant lymphomas].
Diehl V; Engert A
Internist (Berl); 1994 Apr; 35(4):313-22. PubMed ID: 8200756
[No Abstract] [Full Text] [Related]
12. [Therapy of recurrent Hodgkin's lymphoma. II. The value of bone marrow transplantation].
Pfreundschuh M; Diehl V
Dtsch Med Wochenschr; 1989 Jun; 114(23):916-21. PubMed ID: 2656189
[No Abstract] [Full Text] [Related]
13. [Treatment of aggressive non-Hodgkin's lymphomas].
López A; Palacio C
Med Clin (Barc); 1998 May; 110(16):614-8. PubMed ID: 9656199
[No Abstract] [Full Text] [Related]
14. Stem cell transplantation in Hodgkin lymphoma.
Murphy F; Sirohi B; Cunningham D
Expert Rev Anticancer Ther; 2007 Mar; 7(3):297-306. PubMed ID: 17338650
[TBL] [Abstract][Full Text] [Related]
15. BEAM allogeneic transplantation for patients with Hodgkin's disease who relapse after autologous transplantation is safe and effective.
Cooney JP; Stiff PJ; Toor AA; Parthasarathy M
Biol Blood Marrow Transplant; 2003 Mar; 9(3):177-82. PubMed ID: 12652468
[TBL] [Abstract][Full Text] [Related]
16. High-dose busulfan, melphalan, and thiotepa followed by autologous peripheral blood stem cell transplantation in patients with aggressive lymphoma or relapsed Hodgkin's disease.
Schiffman K; Buckner CD; Maziarz R; Maloney DG; Appelbaum FR; Press O; Gooley T; Holmberg L; Lilleby K; Clift R; Zuckerman N; Klarnet J; Weaver C; Chauncey T; Bensinger WI
Biol Blood Marrow Transplant; 1997 Nov; 3(5):261-6. PubMed ID: 9450921
[TBL] [Abstract][Full Text] [Related]
17. Outcome of patients experiencing progression or relapse after primary treatment with two cycles of chemotherapy and radiotherapy for early-stage favorable Hodgkin's lymphoma.
Sieniawski M; Franklin J; Nogova L; Glossmann JP; Schober T; Nisters-Backes H; Diehl V; Josting A
J Clin Oncol; 2007 May; 25(15):2000-5. PubMed ID: 17420510
[TBL] [Abstract][Full Text] [Related]
18. [Status and trends in hematology].
Stobbe H
Z Arztl Fortbild (Jena); 1986; 80(18):741-4. PubMed ID: 3544527
[No Abstract] [Full Text] [Related]
19. [Salvage treatments in non-Hodgkin's lymphoma. I].
Torello E; Koziner B
Sangre (Barc); 1993 Feb; 38(1):37-45. PubMed ID: 8470034
[No Abstract] [Full Text] [Related]
20. [Hodgkin's disease. An old disease with a new face].
Giraldo P; Franco E
Sangre (Barc); 1998 Jun; 43(3):171-3. PubMed ID: 9741220
[No Abstract] [Full Text] [Related]
[Next] [New Search]
